Management of transitional cell XXXX in @entity235 : a review.

@entity1 @entity28 @entity235 @entity5 @entity5450 @entity189 @entity150 @entity1606
@entity1606 ( @entity1606 ), also referred to as @entity189 , is the most common form of @entity150 in @entity235 , affecting tens of thousands of @entity235 worldwide each year. @entity235 @entity1606 is usually a high grade invasive @entity5 . Problems associated with @entity1606 include @entity5450 , distant metastases in >50% of affected @entity235 , and clinical signs that are troubling both to the @entity235 and to their owners. Risk factors for @entity1606 include exposure to older types of flea control products and lawn chemicals, @entity28 , female sex, and a very strong breed-associated risk. This knowledge is allowing pet owners to take steps to reduce the risk of @entity1606 in their @entity235 . The diagnosis of @entity1606 is made by histopathology of tissue biopsies obtained by cystoscopy, surgery, or catheter. Percutaneous aspirates and biopsies should be avoided due to the risk of @entity5 seeding. @entity1606 is most commonly located in the trigone region of the bladder precluding complete surgical resection. Medical treatment is the mainstay for @entity1606 therapy in @entity235 . Although @entity1606 is not usually curable in @entity235 , multiple drugs have activity against it. Approximately 75% of @entity235 respond favorably to @entity1606 treatment and can enjoy several months to a year or more of good quality life. Many promising new therapies for @entity1606 are emerging and with the close similarity between @entity1606 in @entity235 and high grade invasive @entity150 in @entity1 , new treatment strategies found to be successful in @entity235 studies are expected to help @entity235 and to be subsequently translated to @entity1 .
